Last edition
News about "Flowfect Tx cellular engineering platform"
TQ Therapeutics GmbH Enters into Technology Access Agreement with Kytopen
Kytopen has strengthened its European footprint with a new partnership granting TQ Therapeutics on-site access to its non-viral Flowfect Tx cellular engineering platform. The collaboration will support integration of the technology into TQ’s CELLfinity platform.
Flowfect Tx Cellular Engineering Platform | 04/12/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members